Payment overview · 2025
General Payments
$385.25
20 reported records · 8 companies
Healthcare provider profile · identity verified
Jason Robert Hefner, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HOLLY SPRINGS, GA · NPI 1902012206
Verified facts
What the public records show
CMS Open Payments records show Jason Robert Hefner, MD received $385.25 in general payments during 2025 across 20 reported records.
PFIZER INC. accounted for 29.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $114.77 | 29.8% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $94.09 | 24.4% | 6 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $55.75 | 14.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.85 | 9.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.32 | 8.4% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.47 | 5.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.01 | 4.7% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $10.99 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $385.25 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $95.01 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $95.01 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $61.43 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $61.43 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $55.75 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.73 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $10.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 333 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 307 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 257 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 225 | 65 |
| Alprazolam | Alprazolam | 209 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 200 | 60 |
| Lisinopril | Lisinopril | 190 | 61 |
| Gabapentin | Gabapentin | 167 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 153 | 49 |
| Losartan Potassium | Losartan Potassium | 141 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 130 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 129 | 40 |
| Omeprazole | Omeprazole | 124 | 36 |
| Trazodone Hcl | Trazodone Hcl | 120 | 35 |
| Simvastatin | Simvastatin | 116 | 35 |
| Sertraline Hcl | Sertraline Hcl | 110 | 33 |
| Metformin Hcl | Metformin Hcl | 104 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 100 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 19 |
| Metformin Hcl Er | Metformin Hcl | 84 | 26 |
| Ezetimibe | Ezetimibe | 83 | 22 |
| Allopurinol | Allopurinol | 75 | 24 |
| Montelukast Sodium | Montelukast Sodium | 75 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 22 |
| Januvia | Sitagliptin Phosphate | 70 | 18 |
| Meloxicam | Meloxicam | 70 | 29 |
| Furosemide | Furosemide | 67 | 19 |
| Carvedilol | Carvedilol | 66 | 23 |
| Cefdinir | Cefdinir | 66 | 62 |
| Buspirone Hcl | Buspirone Hcl | 65 | 14 |
| Eliquis | Apixaban | 63 | 15 |
| Prednisone | Prednisone | 62 | 46 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 31 |
| Famotidine | Famotidine | 60 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 18 |
| Atenolol | Atenolol | 56 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 19 |
| Ozempic | Semaglutide | 54 | 11 |
| Synthroid | Levothyroxine Sodium | 54 | 17 |
| Temazepam | Temazepam | 53 | 12 |
| Azelastine Hcl | Azelastine Hcl | 51 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 17 |
| Potassium Chloride | Potassium Chloride | 46 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | 14 |
| Ibuprofen | Ibuprofen | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 13 |
| Fenofibrate | Fenofibrate | 39 | 13 |
| Valsartan | Valsartan | 39 | 17 |
| Tramadol Hcl | Tramadol Hcl | 38 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 11 |
| Finasteride | Finasteride | 29 | 11 |
| Celecoxib | Celecoxib | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 12 |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Nystatin | Nystatin | 22 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | 12 |
| Mupirocin | Mupirocin | 14 | 12 |
| Sucralfate | Sucralfate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $385.25 · 20 records | PFIZER INC. | ABRYSVO, COMIRNATY, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, Heplisav-B, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error